This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Endocrine Surgery  • Plastic Surgery  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

Stephen R. Grobmyer, MD; Scott T. Hollenbeck, MD; David P. Jaques, MD; William R. Jarnagin, MD; Ronald DeMatteo, MD; Daniel G. Coit, MD; Leslie H. Blumgart, MD; Murray F. Brennan, MD; Yuman Fong, MD

Arch Surg. 2008;143(12):1184-1188.

Hypothesis  Roux-en-Y reconstruction (RYR) is associated with a reduction in morbidity and mortality associated with pancreatic anastomotic failure after pancreaticoduodenectomy compared with conventional loop reconstruction (CLR).

Design  Retrospective study of patients from 1991 to 2006.

Setting  Tertiary care center.

Patients  Records of patients undergoing CLR (n = 588) and patients undergoing RYR (n = 112) between February 1, 1991, and June 30, 2006, for pancreatic ductal adenocarcinoma at a single institution were retrospectively reviewed and compared.

Main Outcome Measures  Perioperative outcome and mortality were compared for patients who underwent RYR compared with those who underwent CLR.

Results  Overall, both groups required a similar rate of postoperative interventional radiology procedures (CLR, 6.8%; RYR, 9.8%; P = .24) and subsequent operations (CLR, 6.9%; RYR, 9.1%; P = .62). No significant difference was found in the rate of overall postoperative mortality (CLR, 2.6%; RYR, 0.9%; P = .49). The overall rate of pancreatic anastomotic failure was 7.2%, and pancreatic anastomotic failure was associated with a 6% mortality rate. Among patients who developed pancreatic anastomotic failure, no significant difference was seen between CLR (n = 32) and RYR (n = 16) in length of hospital stay (18 vs 19 days; P = .98) or postoperative mortality (3 patients [9.4%] vs none [0%]; P = .54).

Conclusion  We found that RYR is not associated with a reduction in morbidity after pancreaticoduodenectomy for pancreatic adenocarcinoma compared with CLR, even among patients who develop pancreatic anastomotic failure.

Author Affiliations: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. Dr Grobmyer is now with the Division of Surgical Oncology, Department of Surgery, University of Florida, Gainesville.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?